Daily US Times: A review by US regulators of the single-shot Johnson & Johnson Covid-19 vaccine has found it is effective and safe.
J&J vaccine paves the way for it to become the third Covid-19 vaccine to be authorized in the United States, possibly within days.
The vaccine would be a cost-effective alternative to the Moderna and Pfizer vaccines, and can be stored in a refrigerator instead of a freezer.
Last month, results from trials were released by Johnson & Johnson.
The Belgian company Janssen, which is owned by the pharmaceutical giant, said its data showed the vaccine was highly effective against severe disease.
It comes as Ghana became the first country to receive Covax vaccines. Covax is vaccine-sharing initiative.
The briefing document published by the US Food and Drug Administration (FDA) gives more detail on the data submitted by Janssen to the regulator. The FDA concludes that the vaccine has “known benefits” in reducing both severe and symptomatic illness.
Results from the Covid-19 vaccine trials conducted in the US, Brazil and South Africa found its efficacy against the worst outcomes of the virus was “similarly high” but overall protection was lower in Brazil and South Africa, where virus variants have become dominant.
The vaccine was more than 85% effective at preventing serious illness, data reveals, but only 66% effective overall, when moderate cases were included, when considering cases at least 28 days after vaccination.
Notably, there were no deaths among participants who had received the vaccine and no hospital admissions after 28 days post-vaccine.
You may read: World’s first doses of Covax vaccine delivered to Ghana